Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Johnson & Johnson

Pharmaceutical sales up 15% for the year

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson
 
4Q Revenues: $18.3 billion (-1%)

4Q Earnings: $2.5 billion (-29%)

FY Revenues: $74.3 billion (+4%)

FY Earnings: $16.3 billion (+18%)

Comments: Worldwide sales for the year were $74.3 billion, up 4%. Operational results increased 4% and the negative impact of currency was 4.5%. Domestic sales increased 7% while international sales decreased 7%. Worldwide Pharmaceutical sales were $32.3 billion for the year, up 15%, driven by new products and core products including: OLYSIO/SOVRIAD (simeprevir) for chronic hepatitis C; XARELTO (rivaroxaban), an oral anticoagulant; ZYTIGA (abiraterone acetate) for the treatment of metastatic, castration-resistant prostate cancer; INVOKANA (canagliflozin) for type 2 diabetes; and IMBRUVICA (ibrutinib) for certain B-cell malignancies, or blood cancers. Additional core contributors to sales growth were STELARA, INVEGA SUSTENNA/XEPLION, SIMPONI/SIMPONI ARIA, and REMICADE. Worldwide Consumer sales were $14.5 billion, down 1%. Worldwide Medical Devices sales were $27.5 billion, down 3%. 4Q14 earnings included a charge of approximately $1.1 billion, primarily related to an increase in the litigation accrual, integration costs related to the acquisition of Synthes, Inc., and an in-process R&D charge.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters